Market Place
Sourcing Support
FDA’s first generic approvals slump 21% in 2024; Novartis’ top seller Entresto, cancer blockbuster Tasigna lead 2024 patent cliff
A watershed moment in the journey of a drug is when it transitions from being a patented, high‐
Company Tracker: Pfizer turns to acquisitions as Covid products’ sales nosedive
Over the last five years, a
lot has changed for Pfizer Inc, one of the world’s leading pharma
